Core Viewpoint - Rapt Therapeutics (RAPT) shares have increased by 5.8% recently, closing at $8.72, with a mean price target of $24.75 suggesting a potential upside of 183.8% [1][2] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $17.35, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting an 8.3% decline, while the highest estimate is $48.00, indicating a potential surge of 450.5% [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about RAPT's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 24.1%, with one estimate moving higher and no negative revisions [12] - RAPT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can often be inflated due to business incentives, leading to overly optimistic projections [8]

Group 1 - LENZ Therapeutics, Inc. (LENZ) shares have increased by 17% over the past four weeks, closing at $33.73, with a mean price target of $44.14 indicating a potential upside of 30.9% [1] - The average price targets from analysts range from a low of $36.00 to a high of $60.00, with a standard deviation of $8.63, suggesting variability in estimates [2] - Analysts show a consensus that LENZ will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for LENZ's current year earnings has increased by 1.5% over the last 30 days, with one estimate moving higher and no negative revisions [12] - LENZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does suggest a positive direction for price movement [14]

Group 1 - Navigator Holdings (NVGS) closed at $15.45, with a 7.7% gain over the past four weeks, and a mean price target of $21.75 suggests a 40.8% upside potential [1] - The mean estimate includes four short-term price targets with a standard deviation of $2.63, indicating variability among analysts; the lowest estimate is $18.00 (16.5% increase), while the highest is $24.00 (55.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 4.9% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NVGS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of gains, it does suggest a positive direction for price movement [14]

Core Viewpoint - Alkermes (ALKS) shows potential for significant upside, with a mean price target of $40.33 indicating a 33.2% increase from the current price of $30.28 [1] Price Targets and Estimates - The mean estimate consists of 15 short-term price targets with a standard deviation of $6.84, indicating variability among analysts [2] - The lowest estimate is $27.00, suggesting a 10.8% decline, while the highest estimate is $52.00, indicating a potential surge of 71.7% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates - Analysts have shown increasing optimism about Alkermes' earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 1% over the past month, with one estimate rising and no negative revisions [12] - Alkermes holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates [8] - While price targets can provide some guidance, they should be approached with skepticism, as they may not accurately reflect future stock movements [10]

Core Viewpoint - Montrose Environmental (MEG) has shown a slight increase in share price, but analysts suggest there is significant upside potential based on price targets and earnings estimates [1][11]. Price Targets - The mean price target for MEG is $28.83, indicating a potential upside of 25.4% from the current price of $22.99 [1]. - Price targets from analysts range from a low of $18.00 to a high of $35.00, with a standard deviation of $6.55, reflecting variability in estimates [2]. - The lowest estimate suggests a decline of 21.7%, while the highest indicates a potential upside of 52.2% [2]. Analyst Consensus and Earnings Estimates - Analysts have shown increasing optimism regarding MEG's earnings prospects, with a strong agreement in revising EPS estimates higher [11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 4.7%, with one estimate moving higher and no negative revisions [12]. - MEG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10]. - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8]. - A low standard deviation among price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [9].

Trevi Therapeutics, Inc. (TRVI) closed the last trading session at $6.41, gaining 3.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $21.22 indicates a 231.1% upside potential.The average comprises nine short-term price targets ranging from a low of $13.00 to a high of $29.00, with a standard deviation of $4.92. While the lowest estimate indicates an increase of 102.8% from the c ...

Core Viewpoint - Geo Group (GEO) shares have shown a 0.8% increase over the past four weeks, closing at $26.33, with analysts suggesting a potential upside of 58.8% based on a mean price target of $41.8 [1] Price Targets and Analyst Consensus - The average price target for GEO is derived from five short-term estimates, ranging from a low of $35.00 to a high of $50.00, with a standard deviation of $6.42, indicating a potential increase of 32.9% to 89.9% from the current price [2] - A low standard deviation suggests a strong agreement among analysts regarding the price movement of GEO, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher for GEO, which correlates with potential stock price increases [11] - Over the past 30 days, one estimate has increased, leading to a 3.4% rise in the Zacks Consensus Estimate for the current year [12] - GEO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Group 1 - Micron's shares have increased by 8.1% over the past four weeks, closing at $119.92, with a mean price target of $150.72 indicating a potential upside of 25.7% [1] - The mean estimate consists of 29 short-term price targets with a standard deviation of $25.58, where the lowest estimate is $75.00 (37.5% decline) and the highest is $200.00 (66.8% increase) [2] - Analysts show strong agreement on Micron's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for Micron's current year earnings has risen by 11.2% over the past month, with eight estimates increasing and no negative revisions [12] - Micron holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can provide guidance on price movement direction [14]

Group 1 - Kemper's shares have increased by 0.1% over the past four weeks, closing at $63.07, with a mean price target of $82.2 indicating a potential upside of 30.3% [1] - The average of five short-term price targets ranges from a low of $75.00 to a high of $90.00, with a standard deviation of $5.72, suggesting a potential increase of 18.9% to 42.7% from the current price [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, indicating a positive outlook for Kemper [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 0.1% over the last 30 days, with no negative revisions, reflecting optimism about the company's earnings prospects [12] - Kemper currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - VNET Group (VNET) shares have increased by 30.7% in the past four weeks, closing at $6.98, with a mean price target of $12.29 indicating a potential upside of 76.1% according to Wall Street analysts [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.54, indicating variability among analysts [2]. - The lowest estimate is $5.00, suggesting a 28.4% decline from the current price, while the highest estimate is $20.00, indicating a potential increase of 186.5% [2]. - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10]. Earnings Estimates and Analyst Agreement - There is strong agreement among analysts regarding VNET's ability to report better earnings, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11]. - Over the last 30 days, two earnings estimates for VNET have increased, leading to a 21.9% rise in the Zacks Consensus Estimate [12]. - VNET holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]. Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of VNET's potential gains, the implied direction of price movement appears to be a useful guide for investors [14].